GlassScriptPhysician profile
Charles D Woods
NPI 1396748786
$2,997.05
in general payments reported to CMS, 2019-2025
16 companies · $620 in 2025
The $620 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $115 · 2020: $282 · 2021: $394 · 2022: $415 · 2023: $614 · 2024: $558 · 2025: $620.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,565 · Long Term Medical Supply Or Device Loan: $130 · Entertainment: $96.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,564.97 |
| Long Term Medical Supply Or Device Loan | $130.00 |
| Entertainment | $96.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $745.46 | 2022-2025 | Durysta, Lumigan, Alphagan P |
| Alcon Vision LLC | $594.24 | 2019-2025 | Clareon, Argos, Tryptyr |
| Allergan, INC. | $379.18 | 2020-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $304.21 | 2019-2025 | Tecnis Simplicity, Tecnis Iol |
| Ocular Therapeutix, INC. | $254.34 | 2023-2024 | Dextenza |
| Sun Pharmaceutical Industries INC. | $190.96 | 2019-2025 | Cequa |
| Oyster Point Pharma, INC. | $100.01 | 2022-2024 | Tyrvaya, Ryzumvi |
| Nova Eye, INC. | $96.82 | 2025 | |
| Brainlab, INC. | $93.24 | 2020 | |
| Novartis Pharmaceuticals Corporation | $77.02 | 2021-2022 | |
| New World Medical,INC. | $59.67 | 2023 | |
| Tarsus Pharmaceuticals, INC. | $22.54 | 2024 | Xdemvy |
| Sight Sciences, INC. | $22.23 | 2024 | Omni Surgical System |
| Mallinckrodt Hospital Products INC. | $21.02 | 2024 | Acthar |
| Bausch & Lomb Americas INC. | $18.44 | 2025 | Vyzulta |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akorn, INC. | $17.67 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Woods listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.